Hers vs Noom

Which one is actually cheaper, all-in?

Neither company puts its real number in the headline. Hers advertises the Wegovy pill “from $149 a month” — that's the medication only. Add the required Weight Loss Membership ($39 the first month, then $149 a month, billed as its own separate charge) and the real all-in total looks like this once you're past the intro period:

• Wegovy pill: ~$298/mo (medication + membership)
• Wegovy pen: ~$348/mo
• Zepbound: ~$448–$598/mo, rising with dose

Noom folds everything into one number: $249 a month for standard compounded semaglutide, $299 for its tirzepatide tier, with no membership stacked on top.

Compared side by side on a monthly basis, Noom's headline price often reads lower than Hers' all-in total — but Noom doesn't actually bill monthly, which is where the real math shifts. The honest framing isn't “which is cheaper” in the abstract. It's brand-name medication with two smaller charges versus compounded medication with one larger, less frequent one.

Brand-name FDA-approved medication vs. compounded-only

This is the sharpest structural difference between the two. After a February 2026 patent dispute with Novo Nordisk ended in a March 2026 partnership, Hers agreed to stop advertising compounded semaglutide and now sells the actual FDA-approved drugs — the Wegovy pill, the Wegovy pen, and the Zepbound vial — as its default offer; compounded semaglutide survives only as a narrow clinical exception a provider has to justify.

Noom went the opposite direction. Its commercial deal with Eli Lilly for brand-name Zepbound access ended after Noom kept promoting its own microdosed, compounded alternatives, and Lilly pulled out. Every GLP-1 tier in the main Noom Med lineup — standard semaglutide, the microdose option, and the tirzepatide tier — now runs through Noom's own 503A compounding pharmacy. (Noom does have a separate, lower-profile “branded medication” telehealth track that bills insurance and prices a brand-name drug apart from its main plans, but it's not the product most people mean when they say “Noom Med,” and it doesn't come bundled with the coaching app.) If getting an FDA-reviewed, brand-name medication specifically matters to you, that's Hers' clearest edge.

How each one actually bills you

Hers charges twice a month: the membership renews on its own schedule, and the medication renews on its own — two separate line items on your card, which is also why cancelling one doesn't cancel the other. Noom charges once, but rarely: its GLP-1 plans bill as a lump sum every 12 weeks rather than a true monthly charge, so the “$249/mo” or “$299/mo” figure on the pricing page is really a divided-by-three convenience number. In practice that means a charge of roughly $747 to $897 landing on your card every three months instead of a smaller amount every month.

If a large quarterly bill is hard to plan around, Hers' smaller, more frequent charges may suit you better, even though the annual totals land in a similar range.

What you get besides the prescription

Hers' membership buys you access to the care platform: asynchronous messaging with your provider, periodic check-ins as your dose changes, and nutrition guidance inside the app. There is no video call required in most states — you're reviewed and prescribed through your intake, not a live appointment, though a handful of states require one by law.

Noom's price buys something more built-out: its full psychology-based curriculum, daily lessons, food and habit tracking, and coaching content sit on top of the same asynchronous, no-video-required medical review for its compounded tiers. That behavioral layer is genuinely Noom's strongest asset relative to Hers — if you'd actually open the app and use the coaching, you're getting real value for the premium. If you mainly want a prescription and light support, you're paying for a product you won't use.

The legal and reputation red flags worth knowing

Both companies carry documented history, not just internet chatter. The FDA sent Hers a warning letter in September 2025 over how it marketed compounded semaglutide as equivalent to the approved drug — a marketing-language finding, not a safety recall — and that pressure is part of what led to the March 2026 Novo Nordisk deal that ended the dispute and shifted Hers toward brand-name drugs.

Noom's history runs differently: a $62 million class action settlement closed in 2023 over how hard it was to cancel auto-renewing subscriptions on the classic Noom app, and in 2026 the advertising self-regulation body NAD recommended Noom drop or modify its “smarter start” marketing claim for the microdose GLP-1 tier after Eli Lilly challenged it as unsubstantiated. Neither issue is disqualifying on its own, but they point in different directions: Hers' history is regulatory and about the medication itself; Noom's is about subscription and marketing practices.

How easy is each to cancel?

Hers requires cancelling two things — membership and medication — separately, and cancelling one does not cancel the other. Give yourself a few days' buffer before your renewal date and screenshot both confirmations.

Noom's 2023 settlement pushed it toward clearer disclosures and an easier cancellation flow, but its BBB complaint volume remains high despite an A+ rating. Treat cancellation the same way — confirm it went through, then check your statement for a cycle or two afterward, since Noom's quarterly billing means a missed cancellation costs you more per mistake.

Is either built for a 40+, perimenopause body?

No, and it's worth saying plainly. Hers and Noom are both general weight-management platforms with a GLP-1 layered on top; neither evaluates hormone status, offers HRT, or adjusts its protocol for the metabolic shifts that come with declining estrogen. A GLP-1 can still help with the weight itself, but if the wider hormonal picture — sleep, mood, bone density, hot flashes — matters to you too, you're better served pairing that decision with menopause-literate care rather than expecting either platform to handle it. The menopause telehealth comparison is a reasonable next stop if you want to see how HRT-focused providers stack up against a GLP-1-only service like these two.

The real difference

This isn't a “which is cheaper” question so much as a “what are you actually buying” one. Hers sells you the real, FDA-approved drug in two separate monthly charges; Noom sells you a compounded equivalent bundled with real behavioral coaching, billed once every three months. Choose Hers if brand-name matters and you'd rather see two smaller charges than one large one. Choose Noom if you'd genuinely use its coaching platform and you're comfortable with compounded medication and a quarterly bill. Neither is built for a perimenopausal body specifically — that part is on you to add.